Gilead Sciences, Inc. (GILD.NE)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Daniel P. O'Day | Chairman & CEO | 9.87M | -- | 1965 |
| Mr. Andrew D. Dickinson | Chief Financial Officer | 3.77M | 7.65M | 1970 |
| Ms. Deborah H. Telman J.D. | Executive VP of Corporate Affairs, General Counsel & Corporate Secretary | 4.3M | -- | 1965 |
| Ms. Johanna Mercier | Chief Commercial Officer | 4.38M | -- | 1970 |
| Ms. Diane E. Wilfong | Interim Corporate Controller, Chief Accounting Officer & Principal Accounting Officer | -- | -- | 1962 |
| Ms. Jacquie Ross C.F.A. | Vice President of Investor Relations | -- | -- | -- |
| Ms. Jyoti K. Mehra | Executive Vice President of Human Resources | -- | -- | 1977 |
| Dr. Linda Slanec Higgins Ph.D. | Senior Vice President of Research, Innovation & Portfolio | -- | -- | 1962 |
| Dr. Rudolf Ertl | Senior Vice President of Commercial Operations of Australia, Canada, Europe | -- | -- | 1946 |
| Dr. Flavius Martin M.D. | Executive Vice President of Research | -- | -- | -- |
Gilead Sciences, Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 17,600
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Corporate Governance
Upcoming Events
April 24, 2025 at 8:02 PM UTC
Gilead Sciences, Inc. Earnings Date
Recent Events
Recent Events Information Not Available